Home» Renovo Announces the Appointment of Mr Andrew Kay as Executive Director - Commercial
Renovo Announces the Appointment of Mr Andrew Kay as Executive Director - Commercial
4th August 2003
Manchester, UK 4th August 2003
Renovo today announced that Mr Andrew Kay had joined the Company as Executive Director - Commercial. Previously Andrew had been the Global Head of Marketing and Sales and a Member of the Healthcare Committee and Pharmaceutical Executive Committee at Novartis in Basel, Switzerland, where he had worldwide responsibility for the sales and marketing of Novartis’ pharmaceutical portfolio. Andrew has relocated from Basel, Switzerland, to Manchester, England to assume his new responsibilities for Commercial operations within Renovo.
Professor Mark WJ Ferguson, CEO of Renovo, commented “We are delighted to welcome Andrew Kay to Renovo, where his substantial expertise and experience in pharmaceutical marketing will be of great value to Renovo, as its pharmaceutical drugs for the prevention of scarring and acceleration of healing move into later stage clinical trials. This recruitment is a further signal of Renovo’s determination to be a world leading company, not only in scar prevention and wound healing Research and Development, but also in marketing novel, effective pharmaceutical products for these major markets of unmet medical need. I am very pleased that Andrew is joining Renovo’s Executive Management Team and I greatly look forward to working with him in the future”.
Mr Andrew Kay commented “I am delighted to be joining Renovo which is one of the most promising pharmaceutical biotechs with the potential to be a significant research & development and marketing & sales company of the future. Renovo has an attractive pipeline of wound healing and scar prevention products already in phase II and will be entering highly attractive markets where there is great medical need and currently no effective medicines for physicians to offer patients. I look forward to joining a highly talented management team at a time when Renovo is taking its lead products into full development for global launch".
Renovo is a biotechnology company developing novel pharmaceuticals to prevent scarring following all forms of injury, surgery, trauma to various body sites: skin, eyes, internal organs, tendons, ligaments etc and also to accelerate healing e.g., of non-healing wounds – diabetic ulcers, venous ulcers, pressure sores or slowly healing wounds, e.g. in the elderly. Renovo has two pharmaceutical drugs to prevent scarring and accelerate healing in Phase 2 clinical trial, others entering Phase 1 clinical trial and a rich late stage portfolio of additional preclinical candidates. Renovo has it own fully staffed Clinical Trials Unit and typically has ten clinical trials ongoing at any time. Renovo has extensive R&D capability, including major platforms in wound and scar genomics and proteomics. Renovo was founded in October 2000 as a spinout from the University of Manchester and received First Round Financing of £8M (US$12M) from Atlas Venture and JP Morgan. Second Round financing of £23M (US$37M) was completed in January 2003, lead by Healthcap (Stockholm, Sweden) and Care Capital (Princeton, New Jersey), together with Temasek and BioVeda (Singapore) and Atlas Venture and JP Morgan. Further details about Renovo are available on the website www.renovo.com.
For further information, please contact: Renovo Ltd